Compare CubeSmart (CUBE) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Eli Lilly And Co — how do they compare? CubeSmart trades at $37.74 (market cap $8.45B), while Eli Lilly And Co trades at $1,173.23 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 123.1× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.65%). Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Eli Lilly And Co for 93 Days on average.
| CUBE | LLY | |
|---|---|---|
Market Cap | $8.45B | $1.04T |
Volume | 2,879,532 | 3,064,878 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $1.28K |
52-Week Low | $35.36 | $799.57 |
Typical Hold Time | 89 Days | 93 Days |
Enterprise Value | $11.97B | $1.09T |
Dividend Yield | 5.65% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.73, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The REIT maintains strong profitability with 29.41% net margins and consistent dividend payments. Recent Q2 2026 earnings showed operational improvement with revenue beats but FFO misses, prompting raised full-year guidance. Institutional activity remains active with several major funds increasing positions in Q2 2026.
CUBE presents a balanced opportunity with 17% upside to consensus target but faces headwinds from moderating earnings growth and high leverage. The stock offers a 5.4% dividend yield while trading at reasonable valuations (P/E 25.5). Key risks include REIT sector pressure and ongoing macroeconomic uncertainty affecting self-storage demand.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
